Noble Financial Reiterates Buy Rating for Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating restated by analysts at Noble Financial in a research note issued to investors on Sunday, November 12th.

HRTX has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, September 25th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Cowen and Company reiterated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Monday, November 6th. Oppenheimer Holdings, Inc. assumed coverage on shares of Heron Therapeutics in a report on Monday, October 30th. They issued a “buy” rating and a $27.00 price target for the company. Finally, Mizuho reiterated a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and an average target price of $28.36.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up $0.35 during midday trading on Friday, reaching $16.30. 526,900 shares of the company’s stock were exchanged, compared to its average volume of 824,095. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics has a one year low of $12.21 and a one year high of $19.15.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Noble Financial Reiterates Buy Rating for Heron Therapeutics, Inc. (NASDAQ:HRTX)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/11/21/heron-therapeutics-inc-hrtx-rating-reiterated-by-noble-financial.html.

A number of large investors have recently bought and sold shares of HRTX. Parametric Portfolio Associates LLC raised its position in shares of Heron Therapeutics by 2.3% in the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 771 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after purchasing an additional 1,026 shares during the period. Legal & General Group Plc grew its holdings in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,098 shares during the period. HighTower Advisors LLC grew its holdings in shares of Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL grew its holdings in shares of Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 1,724 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply